{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:01:38Z","timestamp":1780128098984,"version":"3.54.0"},"reference-count":123,"publisher":"IMR Press","issue":"5","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Jiangsu Higher Education Institution Innovative Research Team for Science and Technology"},{"name":"Program of Jiangsu Vocational College Engineering Technology Research Center"},{"name":"Program of Suzhou People\u2019s Livelihood Technology Projects","award":["SYWD2024099"],"award-info":[{"award-number":["SYWD2024099"]}]},{"name":"Natural Science Key Foundation of the Jiangsu Higher Education Institutions of China","award":["24KJA310008"],"award-info":[{"award-number":["24KJA310008"]}]},{"name":"Research Foundation of Jiangsu Commission of Health","award":["Z2023031"],"award-info":[{"award-number":["Z2023031"]}]},{"name":"Dongwu Health Talent Program","award":["DWWS2024002"],"award-info":[{"award-number":["DWWS2024002"]}]},{"name":"Programs of the Suzhou Vocational Health College","award":["szwzy202406"],"award-info":[{"award-number":["szwzy202406"]}]},{"name":"Project of Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology","award":["SGK1202413"],"award-info":[{"award-number":["SGK1202413"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Breast cancer, characterized by distinctive epidemiological patterns and substantial heterogeneity, continues to be among the leading causes of cancer-related mortality in women. As breast tumors progressively acquire resistance to doxorubicin (DOX), DNA damage repair (DDR) pathways are recognized as key determinants of both DOX efficacy and the onset of resistance. Targeting DDR mechanisms in breast cancer patients with specific repair deficiencies offers the potential for personalized therapeutic approaches. This review first discusses the pivotal roles of five major DNA repair pathways (homologous recombination, nonhomologous end-joining, base excision repair, nucleotide excision repair, and mismatch repair) in the development of DOX resistance. This review aims to establish a theoretical framework and reference for future studies on DDR mechanisms in DOX-resistant breast cancer to advance intervention strategies for resistant breast tumors and to promote further research in this area.<\/jats:p>","DOI":"10.31083\/fbl47143","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:25:36Z","timestamp":1780125936000},"source":"Crossref","is-referenced-by-count":0,"title":["DNA Damage Repair Pathways and Targeted Therapy for Doxorubicin-Resistant Breast Cancer"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1383-4081","authenticated-orcid":true,"given":"Yijie","family":"Wu","sequence":"first","affiliation":[{"name":"Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Suzhou Vocational Health College, 215009 Suzhou, Jiangsu, China"},{"name":"College of Life Science, North China University of Science and Technology, 063210 Tangshan, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Li","sequence":"additional","affiliation":[{"name":"Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, 215163 Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Life Science, North China University of Science and Technology, 063210 Tangshan, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3920-1032","authenticated-orcid":true,"given":"Song-Bai","family":"Liu","sequence":"additional","affiliation":[{"name":"Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Suzhou Vocational Health College, 215009 Suzhou, Jiangsu, China"},{"name":"College of Life Science, North China University of Science and Technology, 063210 Tangshan, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7335-0203","authenticated-orcid":true,"given":"Xiaohua","family":"Li","sequence":"additional","affiliation":[{"name":"Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Suzhou Vocational Health College, 215009 Suzhou, Jiangsu, China"},{"name":"Thyroid and Breast Surgery, Wuzhong People\u2019s Hospital of Suzhou City, 215128 Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduction and Targeted Therapy. 2025; 10: 49.","DOI":"10.1038\/s41392-024-02108-4"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA: A Cancer Journal for Clinicians. 2024; 74: 477\u2013495.","DOI":"10.3322\/caac.21863"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209\u2013249.","DOI":"10.3322\/caac.21660"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. The New England Journal of Medicine. 2021; 384: 2394\u20132405.","DOI":"10.1056\/NEJMoa2105215"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C, et al. Clinical approaches to overcome PARP inhibitor resistance. Molecular Cancer. 2025; 24: 156.","DOI":"10.1186\/s12943-025-02355-1"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-G\u00e1mez JA, Mart\u00edn-Oliva D, Aguilar-Quesada R, Ca\u00f1uelo A, Nu\u00f1ez MI, Valenzuela MT, et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. The Biochemical Journal. 2005; 386: 119\u2013125.","DOI":"10.1042\/BJ20040776"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. The New England Journal of Medicine. 2022; 387: 9\u201320.","DOI":"10.1056\/NEJMoa2203690"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Johnston S, Emde A, Barrios C, Srock S, Neven P, Martin M, et al. Cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors: existing and emerging differences. JNCI Cancer Spectrum. 2023; 7: pkad045.","DOI":"10.1093\/jncics\/pkad045"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnology and Bioengineering. 1969; 11: 1101\u20131110.","DOI":"10.1002\/bit.260110607"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Arcamone F. Adriamycin and its analogs. Tumori. 1984; 70: 113\u2013119.","DOI":"10.1177\/030089168407000201"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"D\u2019Angelo NA, Noronha MA, C\u00e2mara MCC, Kurnik IS, Feng C, Araujo VHS, et al. Doxorubicin nanoformulations on therapy against cancer: An overview from the last 10 years. Biomaterials Advances. 2022; 133: 112623.","DOI":"10.1016\/j.msec.2021.112623"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Shen Y, Hua Q, Dong M, Jin W, Hu X, Gu K. Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer. Frontiers in Cell and Developmental Biology. 2024; 12: 1448037.","DOI":"10.3389\/fcell.2024.1448037"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Ramayanam NR, Bukke SPN, Moka MK, Dehingia H, Bordoloi A, Debbarma R, et al. Advances in nanoparticle-based doxorubicin delivery: precision strategies for targeted treatment of triple-negative breast cancer. Discover Nano. 2025; 20: 111.","DOI":"10.1186\/s11671-025-04308-5"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Lin Z, Wang L, Xing Z, Wang F, Cheng X. Update on Combination Strategies of PARP Inhibitors. Cancer Control: Journal of the Moffitt Cancer Center. 2024; 31: 10732748241298329.","DOI":"10.1177\/10732748241298329"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Kciuk M, Gieleci\u0144ska A, Mujwar S, Ko\u0142at D, Ka\u0142uzi\u0144ska-Ko\u0142at \u017b, Celik I, et al. Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells. 2023; 12: 659.","DOI":"10.3390\/cells12040659"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. The New England Journal of Medicine. 2010; 363: 1938\u20131948.","DOI":"10.1056\/NEJMra1001389"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Chen Y, Li X, Yang M, Liu SB. Research progress on morphology and mechanism of programmed cell death. Cell Death & Disease. 2024; 15: 327.","DOI":"10.1038\/s41419-024-06712-8"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduction and Targeted Therapy. 2021; 6: 254.","DOI":"10.1038\/s41392-021-00648-7"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Tian Y, Lei Y, Wang Y, Lai J, Wang J, Xia F. Mechanism of multidrug resistance to chemotherapy mediated by P glycoprotein (Review). International Journal of Oncology. 2023; 63: 119.","DOI":"10.3892\/ijo.2023.5567"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Song J, Yang P, Chen C, Ding W, Tillement O, Bai H, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduction and Targeted Therapy. 2025; 10: 219.","DOI":"10.1038\/s41392-025-02266-z"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Tufail M. DNA repair pathways in breast cancer: from mechanisms to clinical applications. Breast Cancer Research and Treatment. 2023; 200: 305\u2013321.","DOI":"10.1007\/s10549-023-06995-z"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Rahimian E, Amini A, Alikarami F, Pezeshki SMS, Saki N, Safa M. DNA repair pathways as guardians of the genome: Therapeutic potential and possible prognostic role in hematologic neoplasms. DNA Repair. 2020; 96: 102951.","DOI":"10.1016\/j.dnarep.2020.102951"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"He C, Kawaguchi K, Toi M. DNA damage repair functions and targeted treatment in breast cancer. Breast Cancer (Tokyo, Japan). 2020; 27: 355\u2013362.","DOI":"10.1007\/s12282-019-01038-2"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Chen NN, Zhou KF, Miao Z, Chen YX, Cui JX, Su SW. Exosomes regulate doxorubicin resistance in breast cancer via miR-34a-5p\/NOTCH1. Molecular and Cellular Probes. 2024; 76: 101964.","DOI":"10.1016\/j.mcp.2024.101964"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Chen NN, Ma XD, Miao Z, Zhang XM, Han BY, Almaamari AA, et al. Doxorubicin resistance in breast cancer is mediated via the activation of FABP5\/PPAR\u03b3 and CaMKII signaling pathway. Frontiers in Pharmacology. 2023; 14: 1150861.","DOI":"10.3389\/fphar.2023.1150861"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Zhao J, Feng Y, Liu GW. Knowledge domains and emerging trends in immune-related adverse events from immune checkpoint inhibitors: A bibliometrics and visualized analysis. Heliyon. 2024; 10: e27832.","DOI":"10.1016\/j.heliyon.2024.e27832"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Liu S, Hua Y, Wang J, Li L, Yuan J, Zhang B, et al. RNA polymerase III is required for the repair of DNA double-strand breaks by homologous recombination. Cell. 2021; 184: 1314\u20131329.e10.","DOI":"10.1016\/j.cell.2021.01.048"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Doig KD, Fellowes AP, Fox SB. Homologous Recombination Repair Deficiency: An Overview for Pathologists. Modern Pathology: an Official Journal of the United States and Canadian Academy of Pathology, Inc. 2023; 36: 100049.","DOI":"10.1016\/j.modpat.2022.100049"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N, et al. Homologous Recombination Deficiency: Concepts, Definitions, and Assays. The Oncologist. 2022; 27: 167\u2013174.","DOI":"10.1093\/oncolo\/oyab053"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Sch\u00fcrmann L, Schumacher L, Roquette K, Brozovic A, Fritz G. Inhibition of the DSB repair protein RAD51 potentiates the cytotoxic efficacy of doxorubicin via promoting apoptosis-related death pathways. Cancer Letters. 2021; 520: 361\u2013373.","DOI":"10.1016\/j.canlet.2021.08.006"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Liu G, Yu M, Wu B, Guo S, Huang X, Zhou F, et al. Jab1\/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51. Cellular Signalling. 2019; 53: 39\u201348.","DOI":"10.1016\/j.cellsig.2018.09.010"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Wang S, Xia Y, Sun Y, Wang W, Shan L, Zhang Z, et al. E2F8-CENPL pathway contributes to homologous recombination repair and chemoresistance in breast cancer. Cellular Signalling. 2024; 118: 111151.","DOI":"10.1016\/j.cellsig.2024.111151"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Passarelli MC, Pinzaru AM, Asgharian H, Liberti MV, Heissel S, Molina H, et al. Leucyl-tRNA synthetase is a tumor suppressor in breast cancer and regulates codon-dependent translation dynamics. Nature Cell Biology. 2022; 24: 307\u2013315.","DOI":"10.1038\/s41556-022-00856-5"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Zhou K, Sun Y, Dong D, Zhao C, Wang W. EMP3 negatively modulates breast cancer cell DNA replication, DNA damage repair, and stem-like properties. Cell Death & Disease. 2021; 12: 844.","DOI":"10.1038\/s41419-021-04140-6"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Zhou Z, Lv J, Yu H, Han J, Yang X, Feng D, et al. Mechanism of RNA modification N6-methyladenosine in human cancer. Molecular Cancer. 2020; 19: 104.","DOI":"10.1186\/s12943-020-01216-3"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Pi J, Wang W, Ji M, Wang X, Wei X, Jin J, et al. YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of FZD7. Cancer Research. 2021; 81: 2651\u20132665.","DOI":"10.1158\/0008-5472.CAN-20-0066"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Caston RA, Gampala S, Armstrong L, Messmann RA, Fishel ML, Kelley MR. The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease. Drug Discovery Today. 2021; 26: 218\u2013228.","DOI":"10.1016\/j.drudis.2020.10.015"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Wells SE, Caldecott KW. KBM-mediated interactions with KU80 promote cellular resistance to DNA replication stress in CHO cells. DNA Repair. 2024; 140: 103710.","DOI":"10.1016\/j.dnarep.2024.103710"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Inagawa T, Wennink T, Lebbink JHG, Keijzers G, Florea BI, Verkaik NS, et al. C-Terminal Extensions of Ku70 and Ku80 Differentially Influence DNA End Binding Properties. International Journal of Molecular Sciences. 2020; 21: 6725.","DOI":"10.3390\/ijms21186725"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Fulne\u010dek J, Klimentov\u00e1 E, Cairo A, Bukovcakova SV, Alexiou P, Prokop Z, et al. The SAP domain of Ku facilitates its efficient loading onto DNA ends. Nucleic Acids Research. 2023; 51: 11706\u201311716.","DOI":"10.1093\/nar\/gkad850"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Lee MG, Lee KS, Nam KS. Combined doxorubicin and arctigenin treatment induce cell cycle arrest-associated cell death by promoting doxorubicin uptake in doxorubicin-resistant breast cancer cells. IUBMB Life. 2023; 75: 765\u2013777.","DOI":"10.1002\/iub.2772"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Novotny JP, Mari\u00f1o-Enr\u00edquez A, Fletcher JA. Targeting DNA-PK. Cancer Treatment and Research. 2023; 186: 299\u2013312.","DOI":"10.1007\/978-3-031-30065-3_16"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Swan RL, Cowell IG, Austin CA. Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes. Molecular Pharmacology. 2022; 101: 24\u201332.","DOI":"10.1124\/molpharm.121.000374"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Revia S, Neumann F, Jabs J, Orio F, Sirrenberg C, Zimmermann A, et al. Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models. International Journal of Molecular Sciences. 2024; 25: 5120.","DOI":"10.3390\/ijms25105120"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Mendoza-Munoz PL, Kushwaha ND, Chauhan D, Ali Gacem KB, Garrett JE, Dynlacht JR, et al. Impact of Optimized Ku-DNA Binding Inhibitors on the Cellular and In Vivo DNA Damage Response. Cancers. 2024; 16: 3286.","DOI":"10.3390\/cancers16193286"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Marino-Enriquez A, Novotny JP, Gulhan DC, Klooster I, Tran AV, Kasbo M, et al. Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2023; 29: 5128\u20135139.","DOI":"10.1158\/1078-0432.CCR-23-0998"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Tang S, Stokasimov E, Cui Y, Pellman D. Breakage of cytoplasmic chromosomes by pathological DNA base excision repair. Nature. 2022; 606: 930\u2013936.","DOI":"10.1038\/s41586-022-04767-1"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Silveira AB, Houy A, Ganier O, \u00d6zemek B, Vanhuele S, Vincent-Salomon A, et al. Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomes. Nature Communications. 2024; 15: 9864.","DOI":"10.1038\/s41467-024-54223-z"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Chen HW, Kuo WH, Lu YS, Chen IC, Hu FC, Wang MY, et al. Interaction of base excision repair gene polymorphism and estrogen-DNA adducts in breast cancer risk among East Asian women. Breast Cancer Research and Treatment. 2024; 208: 283\u2013292.","DOI":"10.1007\/s10549-024-07418-3"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Gautam A, Fawcett H, Burdova K, Brazina J, Caldecott KW. APE1-dependent base excision repair of DNA photodimers in human cells. Molecular Cell. 2023; 83: 3669\u20133678.e7.","DOI":"10.1016\/j.molcel.2023.09.013"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Li J, Zhao H, McMahon A, Yan S. APE1 assembles biomolecular condensates to promote the ATR-Chk1 DNA damage response in nucleolus. Nucleic Acids Research. 2022; 50: 10503\u201310525.","DOI":"10.1093\/nar\/gkac853"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"de Amorim \u00cdSS, Pinheiro D, da Silva Oliveira M, de Sousa Rodrigues MM, Jos\u00e9 JS, Siqueira PB, et al. APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its accumulation and caspase-3\/7-mediated apoptosis. Breast Cancer Research and Treatment. 2025; 209: 533\u2013540.","DOI":"10.1007\/s10549-024-07512-6"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Nian L, Xiaohua L, Rongcheng L, Song-Bai L. Types of DNA damage and research progress. Nucleosides, Nucleotides & Nucleic Acids. 2024; 43: 881\u2013901.","DOI":"10.1080\/15257770.2023.2277194"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Sun H, Lu Z, Singh A, Zhou Y, Zheng E, Zhou M, et al. Error-prone, stress-induced 3\u2019 flap-based Okazaki fragment maturation supports cell survival. Science (New York, N.Y.). 2021; 374: 1252\u20131258.","DOI":"10.1126\/science.abj1013"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Liu N, Du J, Ge J, Liu SB. DNA damage-inducing endogenous and exogenous factors and research progress. Nucleosides, Nucleotides & Nucleic Acids. 2025; 44: 969\u20131001.","DOI":"10.1080\/15257770.2024.2428436"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Lu X, Liu R, Wang M, Kumar AK, Pan F, He L, et al. MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer. Oncogene. 2020; 39: 234\u2013247.","DOI":"10.1038\/s41388-019-0986-0"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Hua AB, Sweasy JB. Functional roles and cancer variants of the bifunctional glycosylase NEIL2. Environmental and Molecular Mutagenesis. 2024; 65: 40\u201356.","DOI":"10.1002\/em.22555"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Banerjee S, Mukherjee S, Bhattacharya A, Basak U, Chakraborty S, Paul S, et al. Pyridoxine enhances chemo-responsiveness of breast cancer stem cells via redox reconditioning. Free Radical Biology & Medicine. 2020; 152: 152\u2013165.","DOI":"10.1016\/j.freeradbiomed.2020.02.031"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Sarker AH, Cooper PK, Hazra TK. DNA glycosylase NEIL2 functions in multiple cellular processes. Progress in Biophysics and Molecular Biology. 2021; 164: 72\u201380.","DOI":"10.1016\/j.pbiomolbio.2021.03.003"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Berfelde J, Hildebrand LS, Kuhlmann L, Fietkau R, Distel LV. FEN1 Inhibition as a Potential Novel Targeted Therapy against Breast Cancer and the Prognostic Relevance of FEN1. International Journal of Molecular Sciences. 2024; 25: 2110.","DOI":"10.3390\/ijms25042110"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Hao Z, Gowder M, Proshkin S, Bharati BK, Epshtein V, Svetlov V, et al. RNA polymerase drives ribonucleotide excision DNA repair in E. coli. Cell. 2023; 186: 2425\u20132437.e21.","DOI":"10.1016\/j.cell.2023.04.029"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Kumar N, Raja S, Van Houten B. The involvement of nucleotide excision repair proteins in the removal of oxidative DNA damage. Nucleic Acids Research. 2020; 48: 11227\u201311243.","DOI":"10.1093\/nar\/gkaa777"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Wang J, He H, Chen B, Jiang G, Cao L, Jiang H, et al. Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation. Nature Communications. 2020; 11: 786.","DOI":"10.1038\/s41467-020-14564-x"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Fu JM, Zhou J, Shi J, Xie JS, Huang L, Yip AYS, et al. Emodin affects ERCC1 expression in breast cancer cells. Journal of Translational Medicine. 2012; 10 Suppl 1: S7.","DOI":"10.1186\/1479-5876-10-S1-S7"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Hanker AB, Sudhan DR, Arteaga CL. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 2020; 37: 496\u2013513.","DOI":"10.1016\/j.ccell.2020.03.009"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Kinnel B, Singh SK, Oprea-Ilies G, Singh R. Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. Cancers. 2023; 15: 1320.","DOI":"10.3390\/cancers15041320"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Lim W, Hwang I, Zhang J, Chen Z, Han J, Jeon J, et al. Exploration of drug resistance mechanisms in triple negative breast cancer cells using a microfluidic device and patient tissues. eLife. 2024; 12: RP88830.","DOI":"10.7554\/eLife.88830"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Lee KJ, Mann E, Wright G, Piett CG, Nagel ZD, Gassman NR. Exploiting DNA repair defects in triple negative breast cancer to improve cell killing. Therapeutic Advances in Medical Oncology. 2020; 12: 1758835920958354.","DOI":"10.1177\/1758835920958354"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Busatto FF, Viero VP, Schaefer BT, Saffi J. Cell growth analysis and nucleotide excision repair modulation in breast cancer cells submitted to a protocol using doxorubicin and paclitaxel. Life Sciences. 2021; 268: 118990.","DOI":"10.1016\/j.lfs.2020.118990"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Khalili-Tanha G, Moghbeli M. Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells. Cellular & Molecular Biology Letters. 2021; 26: 39.","DOI":"10.1186\/s11658-021-00282-9"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Parker KA, Gooding AJ, Valadkhan S, Schiemann WP. lncRNA BORG:TRIM28 Complexes Drive Metastatic Progression by Inducing \u03b16 Integrin\/CD49f Expression in Breast Cancer Stem Cells. Molecular Cancer Research: MCR. 2021; 19: 2068\u20132080.","DOI":"10.1158\/1541-7786.MCR-21-0137"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Gooding AJ, Zhang B, Gunawardane L, Beard A, Valadkhan S, Schiemann WP. The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers. Oncogene. 2019; 38: 2020\u20132041.","DOI":"10.1038\/s41388-018-0586-4"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Incorvaia L, Bazan Russo TD, Gristina V, Perez A, Brando C, Mujacic C, et al. The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors. NPJ Precision Oncology. 2024; 8: 190.","DOI":"10.1038\/s41698-024-00672-0"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Rona G, Miwatani-Minter B, Zhang Q, Goldberg HV, Kerzhnerman MA, Howard JB, et al. CDK-independent role of D-type cyclins in regulating DNA mismatch repair. Molecular Cell. 2024; 84: 1224\u20131242.e13.","DOI":"10.1016\/j.molcel.2024.02.010"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Michaels ML, Cruz C, Grollman AP, Miller JH. Evidence that MutY and MutM combine to prevent mutations by an oxidatively damaged form of guanine in DNA. Proceedings of the National Academy of Sciences of the United States of America. 1992; 89: 7022\u20137025.","DOI":"10.1073\/pnas.89.15.7022"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Kadyrova LY, Mieczkowski PA, Kadyrov FA. MutL\u03b1 suppresses error-prone DNA mismatch repair and preferentially protects noncoding DNA from mutations. Journal of Biological Chemistry. 2024; 300: 107406.","DOI":"10.1016\/j.jbc.2024.107406"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Smith HL, Southgate H, Tweddle DA, Curtin NJ. DNA damage checkpoint kinases in cancer. Expert Reviews in Molecular Medicine. 2020; 22: e2.","DOI":"10.1017\/erm.2020.3"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"DuPrie ML, Palacio T, Calil FA, Kolodner RD, Putnam CD. Mlh1 interacts with both Msh2 and Msh6 for recruitment during mismatch repair. DNA Repair. 2022; 119: 103405.","DOI":"10.1016\/j.dnarep.2022.103405"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Oh JM, Kang Y, Park J, Sung Y, Kim D, Seo Y, et al. MSH2-MSH3 promotes DNA end resection during homologous recombination and blocks polymerase theta-mediated end-joining through interaction with SMARCAD1 and EXO1. Nucleic Acids Research. 2023; 51: 5584\u20135602.","DOI":"10.1093\/nar\/gkad308"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Ponnusamy L, Mahalingaiah PKS, Chang YW, Singh KP. Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences. 2018; 123: 56\u201369.","DOI":"10.1016\/j.ejps.2018.07.028"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, et al. PARP Inhibitors for Breast Cancer Treatment: A Review. JAMA Oncology. 2024; 10: 658\u2013670.","DOI":"10.1001\/jamaoncol.2023.7322"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Li J, Jia Z, Dong L, Cao H, Huang Y, Xu H, et al. DNA damage response in breast cancer and its significant role in guiding novel precise therapies. Biomarker Research. 2024; 12: 111.","DOI":"10.1186\/s40364-024-00653-2"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Liu Q, Chung S, Murata MM, Han B, Gao B, Zhang M, et al. TOP1 inhibition induces bifurcated JNK\/MYC signaling that dictates cancer cell sensitivity. International Journal of Biological Sciences. 2022; 18: 4203\u20134218.","DOI":"10.7150\/ijbs.70583"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Wu Z, Zhu L, Mai J, Shen H, Xu R. Rad51 Silencing with siRNA Delivered by Porous Silicon-Based Microparticle Enhances the Anti-Cancer Effect of Doxorubicin in Triple-Negative Breast Cancer. Journal of Biomedical Nanotechnology. 2021; 17: 2351\u20132363.","DOI":"10.1166\/jbn.2021.3198"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Miyahara S, Miyakoshi H, Yokogawa T, Chong KT, Taguchi J, Muto T, et al. Discovery of a novel class of potent human deoxyuridine triphosphatase inhibitors remarkably enhancing the antitumor activity of thymidylate synthase inhibitors. Journal of Medicinal Chemistry. 2012; 55: 2970\u20132980.","DOI":"10.1021\/jm201628y"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Backer N, Kumar A, Singh AK, Singh H, Narasimhan B, Kumar P. Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer. Drug Discovery Today. 2024; 29: 103853.","DOI":"10.1016\/j.drudis.2023.103853"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Yokogawa T, Yano W, Tsukioka S, Osada A, Wakasa T, Ueno H, et al. dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA-repair-defective human cancer cells. Cancer Science. 2021; 112: 422\u2013432.","DOI":"10.1111\/cas.14718"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Davison C, Morelli R, Knowlson C, McKechnie M, Carson R, Stachtea X, et al. Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer. NPJ Breast Cancer. 2021; 7: 38.","DOI":"10.1038\/s41523-021-00245-5"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Huang F, Mazin AV. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PloS One. 2014; 9: e100993.","DOI":"10.1371\/journal.pone.0100993"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Fernandez A, Artola M, Leon S, Otegui N, Jimeno A, Serrano D, et al. Cancer Vulnerabilities Through Targeting the ATR\/Chk1 and ATM\/Chk2 Axes in the Context of DNA Damage. Cells. 2025; 14: 748.","DOI":"10.3390\/cells14100748"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Qiu Z, Oleinick NL, Zhang J. ATR\/CHK1 inhibitors and cancer therapy. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology. 2018; 126: 450\u2013464.","DOI":"10.1016\/j.radonc.2017.09.043"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Liu G, Zhang Z, Song Q, Guo Y, Bao P, Shui H. Circ_0006528 Contributes to Paclitaxel Resistance of Breast Cancer Cells by Regulating miR-1299\/CDK8 Axis. OncoTargets and Therapy. 2020; 13: 9497\u20139511.","DOI":"10.2147\/OTT.S252886"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Chen LL, Kim VN. Small and long non-coding RNAs: Past, present, and future. Cell. 2024; 187: 6451\u20136485.","DOI":"10.1016\/j.cell.2024.10.024"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Chai Y, Xiang H, Ma Y, Feng W, Jiang Z, Zhu Q, et al. S1PR1 suppresses lung adenocarcinoma progression through p-STAT1\/miR-30c-5 p\/FOXA1 pathway. Journal of Experimental & Clinical Cancer Research: CR. 2024; 43: 304.","DOI":"10.1186\/s13046-024-03230-5"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Yang H, Ren L, Wang Y, Bi X, Li X, Wen M, et al. FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c\/PXR axis. Cell Death & Disease. 2020; 11: 851.","DOI":"10.1038\/s41419-020-03053-0"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Lin S, Yu L, Song X, Bi J, Jiang L, Wang Y, et al. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c\/FANCF\/REV1-mediated DNA damage response. Cell Death & Disease. 2019; 10: 666.","DOI":"10.1038\/s41419-019-1871-z"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Lin S, Yu L, Song X, Bi J, Jiang L, Wang Y, et al. Correction: Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c\/FANCF\/REV1-mediated DNA damage response. Cell Death & Disease. 2022; 13: 82.","DOI":"10.1038\/s41419-022-04543-z"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Chen C, Demirkhanyan L, Gondi CS. The Multifaceted Role of miR-21 in Pancreatic Cancers. Cells. 2024; 13: 948.","DOI":"10.3390\/cells13110948"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Akhtarkhavari T, Bahrami AR, Matin MM. Downregulation of miR-21 as a promising strategy to overcome drug resistance in cancer. European Journal of Pharmacology. 2022; 932: 175233.","DOI":"10.1016\/j.ejphar.2022.175233"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Rama AR, Lara P, Mesas C, Qui\u00f1onero F, V\u00e9lez C, Melguizo C, et al. Circular Sponge against miR-21 Enhances the Antitumor Activity of Doxorubicin against Breast Cancer Cells. International Journal of Molecular Sciences. 2022; 23: 14803.","DOI":"10.3390\/ijms232314803"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Tian JH, Liu SH, Yu CY, Wu LG, Wang LB. The Role of Non-Coding RNAs in Breast Cancer Drug Resistance. Frontiers in Oncology. 2021; 11: 702082.","DOI":"10.3389\/fonc.2021.702082"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Ashrafizaveh S, Ashrafizadeh M, Zarrabi A, Husmandi K, Zabolian A, Shahinozzaman M, et al. Long non-coding RNAs in the doxorubicin resistance of cancer cells. Cancer Letters. 2021; 508: 104\u2013114.","DOI":"10.1016\/j.canlet.2021.03.018"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Wang Y, Zhou P, Li P, Yang F, Gao XQ. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1. Bioengineered. 2020; 11: 536\u2013546.","DOI":"10.1080\/21655979.2020.1761512"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Mintz RL, Lao YH, Chi CW, He S, Li M, Quek CH, et al. CRISPR\/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells. Bioengineering & Translational Medicine. 2020; 5: e10152.","DOI":"10.1002\/btm2.10152"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Corey DR, Damha MJ, Manoharan M. Challenges and Opportunities for Nucleic Acid Therapeutics. Nucleic Acid Therapeutics. 2022; 32: 8\u201313.","DOI":"10.1089\/nat.2021.0085"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Li S, Hu Y, Li A, Lin J, Hsieh K, Schneiderman Z, et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nature Communications. 2022; 13: 5561.","DOI":"10.1038\/s41467-022-33157-4"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Lagunas-Rangel FA, Berm\u00fadez-Cruz RM. Natural Compounds That Target DNA Repair Pathways and Their Therapeutic Potential to Counteract Cancer Cells. Frontiers in Oncology. 2020; 10: 598174.","DOI":"10.3389\/fonc.2020.598174"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"Atanasov AG, Zotchev SB, Dirsch VM, International Natural Product Sciences Taskforce, Supuran CT. Natural products in drug discovery: advances and opportunities. Nature Reviews. Drug Discovery. 2021; 20: 200\u2013216.","DOI":"10.1038\/s41573-020-00114-z"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Sritharan S, Guha S, Hazarika S, Sivalingam N. Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance. Apoptosis: an International Journal on Programmed Cell Death. 2022; 27: 622\u2013646.","DOI":"10.1007\/s10495-022-01742-z"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Chen T, Xiao Z, Liu X, Wang T, Wang Y, Ye F, et al. Natural products for combating multidrug resistance in cancer. Pharmacological Research. 2024; 202: 107099.","DOI":"10.1016\/j.phrs.2024.107099"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Tan Z, Liu J, Hou M, Zhou J, Chen Y, Chen X, et al. Isorhamnetin inhibits cholangiocarcinoma proliferation and metastasis via PI3K\/AKT signaling pathway. Discover Oncology. 2025; 16: 469.","DOI":"10.1007\/s12672-025-02217-8"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Hu J, Zhang Y, Jiang X, Zhang H, Gao Z, Li Y, et al. ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine. Journal of Experimental & Clinical Cancer Research: CR. 2019; 38: 225.","DOI":"10.1186\/s13046-019-1201-4"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Yang T, Xiao Y, Liu S, Luo F, Tang D, Yu Y, et al. Isorhamnetin induces cell cycle arrest and apoptosis by triggering DNA damage and regulating the AMPK\/mTOR\/p70S6K signaling pathway in doxorubicin-resistant breast cancer. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology. 2023; 114: 154780.","DOI":"10.1016\/j.phymed.2023.154780"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Shekhar Kumar, Akanksha Raghuvanshi, Aman Kumar, Vikramdeep Monga. Morin: A Comprehensive Review of Its Sources, Nutraceutical Prospects, Chemistry, and Pharmacological Insights. Phytotherapy Research. 2026; 40: 2651\u20132691.","DOI":"10.1002\/ptr.70274"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Rajput SA, Wang XQ, Yan HC. Morin hydrate: A comprehensive review on novel natural dietary bioactive compound with versatile biological and pharmacological potential. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2021; 138: 111511.","DOI":"10.1016\/j.biopha.2021.111511"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Solairaja S, Andrabi MQ, Dunna NR, Venkatabalasubramanian S. Overview of Morin and Its Complementary Role as an Adjuvant for Anticancer Agents. Nutrition and Cancer. 2021; 73: 927\u2013942.","DOI":"10.1080\/01635581.2020.1778747"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Maharjan S, Lee MG, Lee KS, Nam KS. Morin overcomes doxorubicin resistance in human breast cancer by inducing DNA damage and modulating the LKB1\/AMPK\/mTORC1 signaling pathway. BioFactors (Oxford, England). 2025; 51: e2112.","DOI":"10.1002\/biof.2112"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Mottaghi S, Abbaszadeh H. The anticarcinogenic and anticancer effects of the dietary flavonoid, morin: Current status, challenges, and future perspectives. Phytotherapy Research: PTR. 2021; 35: 6843\u20136861.","DOI":"10.1002\/ptr.7270"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Lei J, Yang J, Bao C, Lu F, Wu Q, Wu Z, et al. Isorhamnetin: what is the in vitro evidence for its antitumor potential and beyond? Frontiers in Pharmacology. 2024; 15: 1309178.","DOI":"10.3389\/fphar.2024.1309178"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Zhao L, Bao C, Shang Y, He X, Ma C, Lei X, et al. The Determinant of DNA Repair Pathway Choices in Ionising Radiation-Induced DNA Double-Strand Breaks. BioMed Research International. 2020; 2020: 4834965.","DOI":"10.1155\/2020\/4834965"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"Seo Y, Tamari K, Takahashi Y, Minami K, Tatekawa S, Isohashi F, et al. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways. International Journal of Radiation Biology. 2022; 98: 1222\u20131234.","DOI":"10.1080\/09553002.2022.2020357"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"Schrempf A, Slyskova J, Loizou JI. Targeting the DNA Repair Enzyme Polymerase \u03b8 in Cancer Therapy. Trends in Cancer. 2021; 7: 98\u2013111.","DOI":"10.1016\/j.trecan.2020.09.007"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"Nguyen L, W M Martens J, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nature Communications. 2020; 11: 5584.","DOI":"10.1038\/s41467-020-19406-4"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/5\/10.31083\/FBL47143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:26:06Z","timestamp":1780125966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/5\/10.31083\/FBL47143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":123,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(25)01958-6"],"URL":"https:\/\/doi.org\/10.31083\/fbl47143","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"47143"}}